Targeted therapy or immunotherapy? Optimal treatment in hepatocellular carcinoma
Author:
Publisher
Baishideng Publishing Group Inc.
Subject
Gastroenterology,Oncology
Reference27 articles.
1. Cancer statistics, 2018
2. Phase III trial of lenvatinib (LEN) vs sorafenib (SOR) in first-line treatment of patients (pts) with unresectable hepatocellular carcinoma (uHCC).
3. Sorafenib in Advanced Hepatocellular Carcinoma
4. Up-titration of sorafenib for hepatocellular carcinoma: Impact on duration of exposure and cost.
5. The effect of sorafenib (S) starting dose and dose intensity on survival in patients with advanced hepatocellular carcinoma (HCC).
Cited by 23 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Immunotherapy and Transarterial therapy of HCC : What the interventional radiologist needs to know about the changing landscape of HCC treatment?;Journal of Medical Imaging and Radiation Oncology;2022-03-31
2. Dipeptidyl peptidase‐8 induces sorafenib resistance via binding with c‐Rel to mediate NF‐κB signaling in hepatocellular carcinoma;Cell Biology International;2021-12-02
3. The Mutation and Expression Level of LRP1B are Associated with Immune Infiltration and Prognosis in Hepatocellular Carcinoma;International Journal of General Medicine;2021-10
4. Healthcare costs related to adverse events in hepatocellular carcinoma treatment: A retrospective observational claims study;Cancer Reports;2021-09-07
5. Amplification of DDR2 mediates sorafenib resistance through NF‐κB/c‐Rel signaling in hepatocellular carcinoma;Cell Biology International;2021-05-16
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3